{
  "model": "chatgpt-gpt-5.3-codex-spark",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 1,
  "result": {
    "text": "âœ… **Completed output files**\n\n- [x] `output/study_overview.json`\n- [x] `output/quantitative_findings.json`\n- [x] `output/claim_audit.json`\n- [x] `output/public_summary.json`",
    "thoughts": "",
    "steps": [
      {
        "step": 1,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": ".",
              "ignore": [
                ".git"
              ],
              "file_filtering_options": {
                "respect_git_ignore": false,
                "respect_gemini_ignore": false
              }
            },
            "output": "input/\noutput/\nschemas/\nTASK.md",
            "callId": "call_1ikfwxXGZKOKah04SrlzciwS"
          }
        ],
        "usage": {
          "promptTokens": 571,
          "cachedTokens": 0,
          "responseTokens": 46,
          "thinkingTokens": 51,
          "totalTokens": 668
        },
        "costUsd": 0.00033675
      },
      {
        "step": 2,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "TASK.md",
              "offset": 0,
              "limit": null
            },
            "output": "L1: # Agent Task\nL2: \nL3: Task id: tumor-vaccine-ici\nL4: Task title: mRNA tumor sensitization for checkpoint blockade\nL5: Reference paper: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL6: Reference URL: https://www.nature.com/articles/s41586-025-09006-8\nL7: \nL8: ## Objective\nL9: Read the report and produce all required JSON outputs that satisfy their schemas.\nL10: \nL11: ## Inputs On Disk\nL12: - Report: `input/report.md`\nL13: - Schemas: in `schemas/`\nL14: \nL15: ## Required Outputs\nL16: - `output/study_overview.json` (schema: `schemas/study_overview.schema.json`)\nL17: - `output/quantitative_findings.json` (schema: `schemas/quantitative_findings.schema.json`)\nL18: - `output/claim_audit.json` (schema: `schemas/claim_audit.schema.json`)\nL19: - `output/public_summary.json` (schema: `schemas/public_summary.schema.json`)\nL20: \nL21: ## Constraints\nL22: - Do not invent source facts; derive calculations only from values in the report.\nL23: - Use line refs as `L<number>` where required.\nL24: - Where quotes are required, copy exact report snippets.\nL25: - For calculation outputs, line_refs must include every report line used for equations, constants, and numeric substitutions.\nL26: - Use relative paths only.\nL27: - Never use absolute paths.\nL28: - Never use `..` in paths.\nL29: - Write valid JSON only.\nL30: \nL31: ## Completion\nL32: Respond with a checklist of written output files.\nL33: After the checklist, stop. Do not call more tools.",
            "callId": "call_5BOL2QVmH3dMofIo5ZhD1oOT"
          }
        ],
        "usage": {
          "promptTokens": 634,
          "cachedTokens": 0,
          "responseTokens": 30,
          "thinkingTokens": 13,
          "totalTokens": 677
        },
        "costUsd": 0.0002445
      },
      {
        "step": 3,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "schemas",
              "ignore": null,
              "file_filtering_options": {
                "respect_git_ignore": false,
                "respect_gemini_ignore": false
              }
            },
            "output": "claim_audit.schema.json\npublic_summary.schema.json\nquantitative_findings.schema.json\nstudy_overview.schema.json",
            "callId": "call_AqM7o8vbQ4uwQUTsHlonMw2q"
          }
        ],
        "usage": {
          "promptTokens": 1084,
          "cachedTokens": 0,
          "responseTokens": 44,
          "thinkingTokens": 57,
          "totalTokens": 1185
        },
        "costUsd": 0.000473
      },
      {
        "step": 4,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/study_overview.schema.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-study_overview\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"paper\": {\nL7:       \"type\": \"object\",\nL8:       \"properties\": {\nL9:         \"title\": {\nL10:           \"type\": \"string\",\nL11:           \"minLength\": 10\nL12:         },\nL13:         \"doi\": {\nL14:           \"type\": \"string\",\nL15:           \"pattern\": \"^10\\\\.\"\nL16:         },\nL17:         \"publication_year\": {\nL18:           \"type\": \"integer\",\nL19:           \"minimum\": 1900,\nL20:           \"maximum\": 2100\nL21:         },\nL22:         \"domain\": {\nL23:           \"type\": \"string\",\nL24:           \"enum\": [\nL25:             \"oncology-immunology\",\nL26:             \"exoplanet-atmospheres\",\nL27:             \"climate-science\",\nL28:             \"neuroscience\",\nL29:             \"other\"\nL30:           ]\nL31:         },\nL32:         \"study_type\": {\nL33:           \"type\": \"string\",\nL34:           \"enum\": [\nL35:             \"preclinical+retrospective\",\nL36:             \"observational-astronomy\",\nL37:             \"randomized-trial\",\nL38:             \"simulation\",\nL39:             \"mixed\"\nL40:           ]\nL41:         }\nL42:       },\nL43:       \"required\": [\nL44:         \"title\",\nL45:         \"doi\",\nL46:         \"publication_year\",\nL47:         \"domain\",\nL48:         \"study_type\"\nL49:       ],\nL50:       \"additionalProperties\": false\nL51:     },\nL52:     \"core_question\": {\nL53:       \"type\": \"string\",\nL54:       \"minLength\": 20\nL55:     },\nL56:     \"datasets_or_cohorts\": {\nL57:       \"type\": \"array\",\nL58:       \"items\": {\nL59:         \"type\": \"object\",\nL60:         \"properties\": {\nL61:           \"id\": {\nL62:             \"type\": \"string\",\nL63:             \"pattern\": \"^[a-z0-9-]+$\"\nL64:           },\nL65:           \"label\": {\nL66:             \"type\": \"string\",\nL67:             \"minLength\": 3\nL68:           },\nL69:           \"sample_size_or_observations\": {\nL70:             \"type\": \"string\",\nL71:             \"minLength\": 1\nL72:           },\nL73:           \"description\": {\nL74:             \"type\": \"string\",\nL75:             \"minLength\": 20\nL76:           }\nL77:         },\nL78:         \"required\": [\nL79:           \"id\",\nL80:           \"label\",\nL81:           \"sample_size_or_observations\",\nL82:           \"description\"\nL83:         ],\nL84:         \"additionalProperties\": false\nL85:       },\nL86:       \"minItems\": 2,\nL87:       \"maxItems\": 8\nL88:     },\nL89:     \"major_limitations\": {\nL90:       \"type\": \"array\",\nL91:       \"items\": {\nL92:         \"type\": \"string\",\nL93:         \"minLength\": 12\nL94:       },\nL95:       \"minItems\": 3,\nL96:       \"maxItems\": 8\nL97:     }\nL98:   },\nL99:   \"required\": [\nL100:     \"paper\",\nL101:     \"core_question\",\nL102:     \"datasets_or_cohorts\",\nL103:     \"major_limitations\"\nL104:   ],\nL105:   \"additionalProperties\": false\nL106: }",
            "callId": "call_ylCtTgcjI9vfrY6dWTYHCSsB"
          }
        ],
        "usage": {
          "promptTokens": 1160,
          "cachedTokens": 0,
          "responseTokens": 33,
          "thinkingTokens": 0,
          "totalTokens": 1193
        },
        "costUsd": 0.000356
      },
      {
        "step": 5,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/quantitative_findings.schema.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-quantitative_findings\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"findings\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^Q[0-9]{2}$\"\nL14:           },\nL15:           \"metric\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 6\nL18:           },\nL19:           \"value\": {\nL20:             \"type\": \"string\",\nL21:             \"minLength\": 1\nL22:           },\nL23:           \"comparator_or_baseline\": {\nL24:             \"type\": \"string\",\nL25:             \"minLength\": 1\nL26:           },\nL27:           \"interpretation\": {\nL28:             \"type\": \"string\",\nL29:             \"minLength\": 12\nL30:           },\nL31:           \"evidence_line_refs\": {\nL32:             \"type\": \"array\",\nL33:             \"items\": {\nL34:               \"type\": \"string\",\nL35:               \"pattern\": \"^L[1-9]\\\\d*$\"\nL36:             },\nL37:             \"minItems\": 1,\nL38:             \"maxItems\": 3\nL39:           }\nL40:         },\nL41:         \"required\": [\nL42:           \"id\",\nL43:           \"metric\",\nL44:           \"value\",\nL45:           \"comparator_or_baseline\",\nL46:           \"interpretation\",\nL47:           \"evidence_line_refs\"\nL48:         ],\nL49:         \"additionalProperties\": false\nL50:       },\nL51:       \"minItems\": 5,\nL52:       \"maxItems\": 14\nL53:     },\nL54:     \"controls_or_null_results\": {\nL55:       \"type\": \"array\",\nL56:       \"items\": {\nL57:         \"type\": \"object\",\nL58:         \"properties\": {\nL59:           \"statement\": {\nL60:             \"type\": \"string\",\nL61:             \"minLength\": 10\nL62:           },\nL63:           \"evidence_line_ref\": {\nL64:             \"$ref\": \"#/definitions/schemas-quantitative_findings/properties/findings/items/properties/evidence_line_refs/items\"\nL65:           }\nL66:         },\nL67:         \"required\": [\nL68:           \"statement\",\nL69:           \"evidence_line_ref\"\nL70:         ],\nL71:         \"additionalProperties\": false\nL72:       },\nL73:       \"minItems\": 2,\nL74:       \"maxItems\": 10\nL75:     }\nL76:   },\nL77:   \"required\": [\nL78:     \"findings\",\nL79:     \"controls_or_null_results\"\nL80:   ],\nL81:   \"additionalProperties\": false\nL82: }",
            "callId": "call_mxav03qyybZfJ2rY8A6ufbQ9"
          }
        ],
        "usage": {
          "promptTokens": 2110,
          "cachedTokens": 1024,
          "responseTokens": 34,
          "thinkingTokens": 0,
          "totalTokens": 2144
        },
        "costUsd": 0.00036510000000000004
      },
      {
        "step": 6,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/claim_audit.schema.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-claim_audit\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"claims\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"claim_id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^C[0-9]{2}$\"\nL14:           },\nL15:           \"claim\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 20\nL18:           },\nL19:           \"strength\": {\nL20:             \"type\": \"string\",\nL21:             \"enum\": [\nL22:               \"strong\",\nL23:               \"moderate\",\nL24:               \"tentative\"\nL25:             ]\nL26:           },\nL27:           \"evidence\": {\nL28:             \"type\": \"array\",\nL29:             \"items\": {\nL30:               \"type\": \"object\",\nL31:               \"properties\": {\nL32:                 \"quote\": {\nL33:                   \"type\": \"string\",\nL34:                   \"minLength\": 10\nL35:                 },\nL36:                 \"line_ref\": {\nL37:                   \"type\": \"string\",\nL38:                   \"pattern\": \"^L[1-9]\\\\d*$\"\nL39:                 }\nL40:               },\nL41:               \"required\": [\nL42:                 \"quote\",\nL43:                 \"line_ref\"\nL44:               ],\nL45:               \"additionalProperties\": false\nL46:             },\nL47:             \"minItems\": 2,\nL48:             \"maxItems\": 3\nL49:           },\nL50:           \"caveat\": {\nL51:             \"type\": \"string\",\nL52:             \"minLength\": 20\nL53:           }\nL54:         },\nL55:         \"required\": [\nL56:           \"claim_id\",\nL57:           \"claim\",\nL58:           \"strength\",\nL59:           \"evidence\",\nL60:           \"caveat\"\nL61:         ],\nL62:         \"additionalProperties\": false\nL63:       },\nL64:       \"minItems\": 4,\nL65:       \"maxItems\": 10\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"claims\"\nL70:   ],\nL71:   \"additionalProperties\": false\nL72: }",
            "callId": "call_zrVHba9c5SdDo4cOGN3pCj6G"
          }
        ],
        "usage": {
          "promptTokens": 2890,
          "cachedTokens": 1920,
          "responseTokens": 33,
          "thinkingTokens": 0,
          "totalTokens": 2923
        },
        "costUsd": 0.00035649999999999994
      },
      {
        "step": 7,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/public_summary.schema.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-public_summary\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"headline\": {\nL7:       \"type\": \"string\",\nL8:       \"minLength\": 20,\nL9:       \"maxLength\": 120\nL10:     },\nL11:     \"plain_language_summary\": {\nL12:       \"type\": \"string\",\nL13:       \"minLength\": 180,\nL14:       \"maxLength\": 1200\nL15:     },\nL16:     \"what_is_new\": {\nL17:       \"type\": \"array\",\nL18:       \"items\": {\nL19:         \"type\": \"string\",\nL20:         \"minLength\": 20\nL21:       },\nL22:       \"minItems\": 3,\nL23:       \"maxItems\": 3\nL24:     },\nL25:     \"why_caution_is_needed\": {\nL26:       \"type\": \"array\",\nL27:       \"items\": {\nL28:         \"type\": \"string\",\nL29:         \"minLength\": 20\nL30:       },\nL31:       \"minItems\": 3,\nL32:       \"maxItems\": 5\nL33:     },\nL34:     \"glossary\": {\nL35:       \"type\": \"array\",\nL36:       \"items\": {\nL37:         \"type\": \"object\",\nL38:         \"properties\": {\nL39:           \"term\": {\nL40:             \"type\": \"string\",\nL41:             \"minLength\": 2\nL42:           },\nL43:           \"definition\": {\nL44:             \"type\": \"string\",\nL45:             \"minLength\": 20,\nL46:             \"maxLength\": 220\nL47:           }\nL48:         },\nL49:         \"required\": [\nL50:           \"term\",\nL51:           \"definition\"\nL52:         ],\nL53:         \"additionalProperties\": false\nL54:       },\nL55:       \"minItems\": 4,\nL56:       \"maxItems\": 8\nL57:     },\nL58:     \"open_questions\": {\nL59:       \"type\": \"array\",\nL60:       \"items\": {\nL61:         \"type\": \"string\",\nL62:         \"minLength\": 20\nL63:       },\nL64:       \"minItems\": 3,\nL65:       \"maxItems\": 6\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"headline\",\nL70:     \"plain_language_summary\",\nL71:     \"what_is_new\",\nL72:     \"why_caution_is_needed\",\nL73:     \"glossary\",\nL74:     \"open_questions\"\nL75:   ],\nL76:   \"additionalProperties\": false\nL77: }",
            "callId": "call_cuMlpUqkL4Gj8RgozHFHdUTm"
          }
        ],
        "usage": {
          "promptTokens": 3537,
          "cachedTokens": 2688,
          "responseTokens": 31,
          "thinkingTokens": 0,
          "totalTokens": 3568
        },
        "costUsd": 0.00034145
      },
      {
        "step": 8,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "input/report.md",
              "offset": 0,
              "limit": null
            },
            "output": "L1: # Structured Paper Report: Tumor Sensitization by mRNA Vaccination\nL2: \nL3: ## Citation\nL4: - Title: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL5: - Journal: Nature\nL6: - Year: 2025\nL7: - DOI: 10.1038/s41586-025-09006-8\nL8: - Source URL: https://www.nature.com/articles/s41586-025-09006-8\nL9: \nL10: ## One-Paragraph Context\nL11: Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors remain non-responsive due to weak antigen presentation or poor immune priming. The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\nL12: \nL13: ## Study Design Snapshot\nL14: - Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\nL15: - Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\nL16: - Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\nL17: \nL18: ## Cohorts and Scenarios\nL19: 1. Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\nL20: 2. Mouse control cohort (vaccine only, ICI only, and vehicle): 84 tumor-bearing mice pooled across matched controls.\nL21: 3. Human retrospective metastatic cohort: 130 patients total.\nL22: 4. Human vaccinated subgroup: 43 patients.\nL23: 5. Human unvaccinated subgroup: 87 patients.\nL24: \nL25: ## Quantitative Findings\nL26: | Metric | Vaccine/Combination Arm | Comparator | Interpretation |\nL27: |---|---:|---:|---|\nL28: | Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\nL29: | Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\nL30: | Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\nL31: | Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\nL32: | PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\nL33: | Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\nL34: \nL35: ## Controls and Null/Conditional Results\nL36: - Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\nL37: - ICI-only treatment had limited activity in low-immunogenic baseline settings.\nL38: - Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\nL39: - Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\nL40: \nL41: ## Mechanistic Chain Proposed by Authors\nL42: 1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\nL43: 2. Interferon-associated antigen processing and presentation pathways increase.\nL44: 3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\nL45: 4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\nL46: 5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\nL47: \nL48: ## Caveats and Threats to Validity\nL49: - The human analysis is retrospective and non-randomized; residual confounding is likely.\nL50: - Vaccination timing relative to ICI initiation varied across patients.\nL51: - Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\nL52: - Mouse model effects may not map one-to-one to all human tumors.\nL53: - Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\nL54: \nL55: ## Practical Takeaway\nL56: The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.",
            "callId": "call_SYBjxy8dLcpPAng11zoYRuH2"
          }
        ],
        "usage": {
          "promptTokens": 4254,
          "cachedTokens": 3456,
          "responseTokens": 31,
          "thinkingTokens": 23,
          "totalTokens": 4308
        },
        "costUsd": 0.0003939
      },
      {
        "step": 9,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/study_overview.json",
              "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral mRNA vaccination increase tumor sensitivity to anti-PD-L1 immune checkpoint blockade, and are the findings consistent in both murine models and retrospective human ICI-treated patients?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-cohort\",\n      \"label\": \"Mouse efficacy cohort\",\n      \"sample_size_or_observations\": \"78 mice (pooled across repeat experiments)\",\n      \"description\": \"Murine efficacy studies testing intratumoral mRNA vaccination combined with anti-PD-L1 in multiple tumor models.\"\n    },\n    {\n      \"id\": \"mouse-control-cohort\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84 mice (pooled across matched controls)\",\n      \"description\": \"Matched murine controls receiving vaccine-only, ICI-only, and vehicle treatment for comparison against sensitization outcomes.\"\n    },\n    {\n      \"id\": \"human-retrospective-cohort\",\n      \"label\": \"Human retrospective cohort\",\n      \"sample_size_or_observations\": \"130 metastatic patients\",\n      \"description\": \"Metastatic patients receiving immune checkpoint inhibitors, analyzed retrospectively by prior SARS-CoV-2 mRNA vaccination status.\"\n    },\n    {\n      \"id\": \"human-vaccinated-subgroup\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subset of the retrospective cohort previously vaccinated with a SARS-CoV-2 mRNA vaccine before/around ICI treatment.\"\n    },\n    {\n      \"id\": \"human-unvaccinated-subgroup\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Comparison group of metastatic patients without documented SARS-CoV-2 mRNA vaccination for survival and clinical outcome contrasts.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized, so residual confounding is likely. \",\n    \"Vaccination timing relative to ICI initiation varied across patients. \",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation. \",\n    \"Mouse model effects may not map one-to-one to all human tumors. \",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all settings. \"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/study_overview.json",
            "callId": "call_c2XFEeIgvd3vF0MJE2rHU4Mi"
          }
        ],
        "usage": {
          "promptTokens": 5358,
          "cachedTokens": 4096,
          "responseTokens": 688,
          "thinkingTokens": 2388,
          "totalTokens": 8434
        },
        "costUsd": 0.006569899999999999
      },
      {
        "step": 10,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Tumor immunopeptidome breadth\",\n      \"value\": \"62.3% vs 37.3%\",\n      \"comparator_or_baseline\": \"vaccine/combination arm versus comparator condition\",\n      \"interpretation\": \"Intratumoral mRNA-vaccinated or combination-treated tumors showed a notably larger fraction of proteins represented in the immunopeptidome, indicating broader antigen display.\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"MHC-I peptide landscape breadth\",\n      \"value\": \"40.6% vs 20.6%\",\n      \"comparator_or_baseline\": \"combination or vaccine arm versus comparator\",\n      \"interpretation\": \"MHC-I-presented proteins roughly doubled, supporting expansion of the antigenic peptide repertoire potentially more visible to CD8+ responses.\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective survival association under ICI\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"vaccinated versus unvaccinated subgroup\",\n      \"interpretation\": \"Vaccinated patients in the metastatic cohort had improved survival compared with unvaccinated patients under ICI treatment, reaching the reported significance threshold.\",\n      \"evidence_line_refs\": [\"L30\", \"L21\", \"L23\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score\",\n      \"value\": \"3.1 normalized units\",\n      \"comparator_or_baseline\": \"1.0 baseline normalized units\",\n      \"interpretation\": \"The reported normalized interferon response increased after intratumoral mRNA vaccination, consistent with innate activation in tumors.\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression change\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x baseline\",\n      \"interpretation\": \"PD-L1 levels increased in tumor tissue, supporting the biologic rationale for combining with checkpoint blockade.\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x baseline\",\n      \"interpretation\": \"CD8+ T-cell density increased approximately 1.8-fold, consistent with improved immune infiltration after sensitization strategies.\",\n      \"evidence_line_refs\": [\"L33\"]\n    },\n    {\n      \"id\": \"Q07\",\n      \"metric\": \"Mouse sample size\",\n      \"value\": \"78 mice efficacy / 84 mice controls\",\n      \"comparator_or_baseline\": \"pooled across repeat experiments and matched controls\",\n      \"interpretation\": \"The preclinical evidence combines substantial mouse observations from both efficacy and control arms to contrast treatment combinations and controls.\",\n      \"evidence_line_refs\": [\"L19\", \"L20\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce sensitization benefits.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json",
            "callId": "call_aUGdOjbQQTQtQ5wnHWLGx73b"
          }
        ],
        "usage": {
          "promptTokens": 6065,
          "cachedTokens": 5248,
          "responseTokens": 1000,
          "thinkingTokens": 793,
          "totalTokens": 7858
        },
        "costUsd": 0.00392145
      },
      {
        "step": 11,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination can broaden tumor antigen presentation and increase immune visibility.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Broader antigen display after intratumoral mRNA vaccination\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        }\n      ],\n      \"caveat\": \"The report does not describe exact statistical tests or effect sizes for every model, and mechanisms varied by model system.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"The treatment strategy induced interferon-associated activation and increased PD-L1 signaling, providing mechanistic rationale for combining with checkpoint blockade.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Interferon-associated antigen processing and presentation pathways increase.\",\n          \"line_ref\": \"L43\"\n        },\n        {\n          \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\n          \"line_ref\": \"L45\"\n        },\n        {\n          \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\n          \"line_ref\": \"L31\"\n        }\n      ],\n      \"caveat\": \"The report notes strongest mechanistic readouts in specific model systems, so breadth of this mechanism across all tumors is uncertain.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Combination of intratumoral mRNA vaccine and anti-PD-L1 improves preclinical tumor control relative to controls.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\",\n          \"line_ref\": \"L14\"\n        },\n        {\n          \"quote\": \"Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy.\",\n          \"line_ref\": \"L33\"\n        }\n      ],\n      \"caveat\": \"The report does not provide explicit response curves or hazard statistics for all experiments, and non-immunogenic models had limited benefit from vaccine-only treatment.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Retrospective human data indicate vaccinated metastatic patients under ICI had better survival than unvaccinated patients.\n      \",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n          \"line_ref\": \"L49\"\n        }\n      ],\n      \"caveat\": \"This is an observational retrospective cohort with potential confounding and variable vaccination timing, so causal claims are limited.\"\n    }\n  ]\n}"
            },
            "output": "Successfully wrote file: output/claim_audit.json",
            "callId": "call_OlZvLMplTkeQTVO7EhABOGqp"
          }
        ],
        "usage": {
          "promptTokens": 7085,
          "cachedTokens": 5888,
          "responseTokens": 846,
          "thinkingTokens": 0,
          "totalTokens": 7931
        },
        "costUsd": 0.00213845
      },
      {
        "step": 12,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Can intratumoral mRNA vaccination increase tumor sensitivity to anti-PD-L1 immune checkpoint blockade, and are the findings consistent in both murine models and retrospective human ICI-treated patients?\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy-cohort\",\nL13:       \"label\": \"Mouse efficacy cohort\",\nL14:       \"sample_size_or_observations\": \"78 mice (pooled across repeat experiments)\",\nL15:       \"description\": \"Murine efficacy studies testing intratumoral mRNA vaccination combined with anti-PD-L1 in multiple tumor models.\"\nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-control-cohort\",\nL19:       \"label\": \"Mouse control cohort\",\nL20:       \"sample_size_or_observations\": \"84 mice (pooled across matched controls)\",\nL21:       \"description\": \"Matched murine controls receiving vaccine-only, ICI-only, and vehicle treatment for comparison against sensitization outcomes.\"\nL22:     },\nL23:     {\nL24:       \"id\": \"human-retrospective-cohort\",\nL25:       \"label\": \"Human retrospective cohort\",\nL26:       \"sample_size_or_observations\": \"130 metastatic patients\",\nL27:       \"description\": \"Metastatic patients receiving immune checkpoint inhibitors, analyzed retrospectively by prior SARS-CoV-2 mRNA vaccination status.\"\nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated-subgroup\",\nL31:       \"label\": \"Human vaccinated subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Subset of the retrospective cohort previously vaccinated with a SARS-CoV-2 mRNA vaccine before/around ICI treatment.\"\nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated-subgroup\",\nL37:       \"label\": \"Human unvaccinated subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Comparison group of metastatic patients without documented SARS-CoV-2 mRNA vaccination for survival and clinical outcome contrasts.\"\nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"The human analysis is retrospective and non-randomized, so residual confounding is likely. \",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients. \",\nL45:     \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation. \",\nL46:     \"Mouse model effects may not map one-to-one to all human tumors. \",\nL47:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all settings. \"\nL48:   ]\nL49: }",
            "callId": "call_0SvnKZ6YluAICVL3wNkVZuUL"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"findings\": [\nL3:     {\nL4:       \"id\": \"Q01\",\nL5:       \"metric\": \"Tumor immunopeptidome breadth\",\nL6:       \"value\": \"62.3% vs 37.3%\",\nL7:       \"comparator_or_baseline\": \"vaccine/combination arm versus comparator condition\",\nL8:       \"interpretation\": \"Intratumoral mRNA-vaccinated or combination-treated tumors showed a notably larger fraction of proteins represented in the immunopeptidome, indicating broader antigen display.\",\nL9:       \"evidence_line_refs\": [\"L28\"]\nL10:     },\nL11:     {\nL12:       \"id\": \"Q02\",\nL13:       \"metric\": \"MHC-I peptide landscape breadth\",\nL14:       \"value\": \"40.6% vs 20.6%\",\nL15:       \"comparator_or_baseline\": \"combination or vaccine arm versus comparator\",\nL16:       \"interpretation\": \"MHC-I-presented proteins roughly doubled, supporting expansion of the antigenic peptide repertoire potentially more visible to CD8+ responses.\",\nL17:       \"evidence_line_refs\": [\"L29\"]\nL18:     },\nL19:     {\nL20:       \"id\": \"Q03\",\nL21:       \"metric\": \"Retrospective survival association under ICI\",\nL22:       \"value\": \"p=0.01\",\nL23:       \"comparator_or_baseline\": \"vaccinated versus unvaccinated subgroup\",\nL24:       \"interpretation\": \"Vaccinated patients in the metastatic cohort had improved survival compared with unvaccinated patients under ICI treatment, reaching the reported significance threshold.\",\nL25:       \"evidence_line_refs\": [\"L30\", \"L21\", \"L23\"]\nL26:     },\nL27:     {\nL28:       \"id\": \"Q04\",\nL29:       \"metric\": \"Type I interferon response score\",\nL30:       \"value\": \"3.1 normalized units\",\nL31:       \"comparator_or_baseline\": \"1.0 baseline normalized units\",\nL32:       \"interpretation\": \"The reported normalized interferon response increased after intratumoral mRNA vaccination, consistent with innate activation in tumors.\",\nL33:       \"evidence_line_refs\": [\"L31\"]\nL34:     },\nL35:     {\nL36:       \"id\": \"Q05\",\nL37:       \"metric\": \"PD-L1 expression change\",\nL38:       \"value\": \"2.4x\",\nL39:       \"comparator_or_baseline\": \"1.0x baseline\",\nL40:       \"interpretation\": \"PD-L1 levels increased in tumor tissue, supporting the biologic rationale for combining with checkpoint blockade.\",\nL41:       \"evidence_line_refs\": [\"L32\"]\nL42:     },\nL43:     {\nL44:       \"id\": \"Q06\",\nL45:       \"metric\": \"Intratumoral CD8+ T-cell density\",\nL46:       \"value\": \"1.8x\",\nL47:       \"comparator_or_baseline\": \"1.0x baseline\",\nL48:       \"interpretation\": \"CD8+ T-cell density increased approximately 1.8-fold, consistent with improved immune infiltration after sensitization strategies.\",\nL49:       \"evidence_line_refs\": [\"L33\"]\nL50:     },\nL51:     {\nL52:       \"id\": \"Q07\",\nL53:       \"metric\": \"Mouse sample size\",\nL54:       \"value\": \"78 mice efficacy / 84 mice controls\",\nL55:       \"comparator_or_baseline\": \"pooled across repeat experiments and matched controls\",\nL56:       \"interpretation\": \"The preclinical evidence combines substantial mouse observations from both efficacy and control arms to contrast treatment combinations and controls.\",\nL57:       \"evidence_line_refs\": [\"L19\", \"L20\"]\nL58:     }\nL59:   ],\nL60:   \"controls_or_null_results\": [\nL61:     {\nL62:       \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\nL63:       \"evidence_line_ref\": \"L36\"\nL64:     },\nL65:     {\nL66:       \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\nL67:       \"evidence_line_ref\": \"L37\"\nL68:     },\nL69:     {\nL70:       \"statement\": \"Lipid particle controls lacking mRNA did not reproduce sensitization benefits.\",\nL71:       \"evidence_line_ref\": \"L38\"\nL72:     },\nL73:     {\nL74:       \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the sensitization benefit.\",\nL75:       \"evidence_line_ref\": \"L39\"\nL76:     }\nL77:   ]\nL78: }",
            "callId": "call_Fhnc8pEZ49ycwkCNkWfqjI9n"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"claims\": [\nL3:     {\nL4:       \"claim_id\": \"C01\",\nL5:       \"claim\": \"Intratumoral mRNA vaccination can broaden tumor antigen presentation and increase immune visibility.\",\nL6:       \"strength\": \"strong\",\nL7:       \"evidence\": [\nL8:         {\nL9:           \"quote\": \"Broader antigen display after intratumoral mRNA vaccination\",\nL10:           \"line_ref\": \"L28\"\nL11:         },\nL12:         {\nL13:           \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\nL14:           \"line_ref\": \"L44\"\nL15:         }\nL16:       ],\nL17:       \"caveat\": \"The report does not describe exact statistical tests or effect sizes for every model, and mechanisms varied by model system.\"\nL18:     },\nL19:     {\nL20:       \"claim_id\": \"C02\",\nL21:       \"claim\": \"The treatment strategy induced interferon-associated activation and increased PD-L1 signaling, providing mechanistic rationale for combining with checkpoint blockade.\",\nL22:       \"strength\": \"strong\",\nL23:       \"evidence\": [\nL24:         {\nL25:           \"quote\": \"Interferon-associated antigen processing and presentation pathways increase.\",\nL26:           \"line_ref\": \"L43\"\nL27:         },\nL28:         {\nL29:           \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\nL30:           \"line_ref\": \"L45\"\nL31:         },\nL32:         {\nL33:           \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\nL34:           \"line_ref\": \"L31\"\nL35:         }\nL36:       ],\nL37:       \"caveat\": \"The report notes strongest mechanistic readouts in specific model systems, so breadth of this mechanism across all tumors is uncertain.\"\nL38:     },\nL39:     {\nL40:       \"claim_id\": \"C03\",\nL41:       \"claim\": \"Combination of intratumoral mRNA vaccine and anti-PD-L1 improves preclinical tumor control relative to controls.\",\nL42:       \"strength\": \"moderate\",\nL43:       \"evidence\": [\nL44:         {\nL45:           \"quote\": \"Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\",\nL46:           \"line_ref\": \"L14\"\nL47:         },\nL48:         {\nL49:           \"quote\": \"Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy.\",\nL50:           \"line_ref\": \"L33\"\nL51:         }\nL52:       ],\nL53:       \"caveat\": \"The report does not provide explicit response curves or hazard statistics for all experiments, and non-immunogenic models had limited benefit from vaccine-only treatment.\"\nL54:     },\nL55:     {\nL56:       \"claim_id\": \"C04\",\nL57:       \"claim\": \"Retrospective human data indicate vaccinated metastatic patients under ICI had better survival than unvaccinated patients.\nL58:       \",\nL59:       \"strength\": \"tentative\",\nL60:       \"evidence\": [\nL61:         {\nL62:           \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\nL63:           \"line_ref\": \"L30\"\nL64:         },\nL65:         {\nL66:           \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL67:           \"line_ref\": \"L49\"\nL68:         }\nL69:       ],\nL70:       \"caveat\": \"This is an observational retrospective cohort with potential confounding and variable vaccination timing, so causal claims are limited.\"\nL71:     }\nL72:   ]\nL73: }",
            "callId": "call_qHzwM2GP8jhLMs2cj1zIL5Up"
          }
        ],
        "usage": {
          "promptTokens": 7952,
          "cachedTokens": 6912,
          "responseTokens": 107,
          "thinkingTokens": 252,
          "totalTokens": 8311
        },
        "costUsd": 0.0011508
      },
      {
        "step": 13,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"Tumor-targeted mRNA vaccines may prime cancers for stronger anti-PD-L1 responses\",\n  \"plain_language_summary\": \"Researchers tested whether giving an mRNA vaccine directly inside a tumor can make that tumor more sensitive to immune checkpoint blockade. In mice, combining intratumoral mRNA vaccination with anti-PD-L1 was linked to stronger immune signatures, including broader antigen presentation, higher PD-L1 expression, and more CD8+ T-cell infiltration. In a separate retrospective review of 130 metastatic patients on ICI treatment, vaccinated patients (43) had better survival signals than unvaccinated patients (87), with a reported p-value of 0.01. The study also found that the benefit depended on type I interferon pathways and was lost when interferon signaling was blocked, and non-mRNA particle controls failed to reproduce the effect. While encouraging, the human signal is observational and not randomized, so larger prospective trials are still needed before changing clinical practice.\n  \",\n  \"what_is_new\": [\n    \"The work links local mRNA vaccination in the tumor with broadening of the tumor immunopeptidome and MHC-I presented antigens, which can improve immune recognition of the tumor. \",\n    \"It combines murine efficacy experiments with a real-world metastatic patient analysis to connect mechanism, preclinical response, and retrospective clinical associations. \",\n    \"Mechanistically, the effect appears tied to type I interferon signaling, with anti-IFNAR1 blockade abolishing sensitization and non-mRNA lipid particles failing to mimic the benefit.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human comparison was retrospective and non-randomized, so unmeasured confounding and baseline group differences could influence survival associations. \",\n    \"Vaccination timing relative to ICI start varied across patients, making it hard to attribute timing-specific efficacy claims to the vaccine effect alone. \",\n    \"Tumor-type mix and prior treatment heterogeneity were present, and mouse-to-human translation is not guaranteed across all cancers and contexts. \"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"ICI\",\n      \"definition\": \"Immune checkpoint inhibitors; drugs like anti-PD-L1 that block inhibitory signals on immune cells so T-cells can attack tumors more effectively.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A surface molecule type on cells that presents protein fragments to CD8+ T-cells, helping immune cells recognize cancer cells.\"\n    },\n    {\n      \"term\": \"Interferon signaling\",\n      \"definition\": \"A cell communication pathway (especially type I interferons) that increases antiviral-like immune activation and antigen presentation in tissues.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The full set of peptides displayed on MHC molecules by a cell, which can be measured to estimate how visible that cell is to the immune system.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Do these findings hold in a prospective randomized human trial with predefined vaccination timing and standardized ICI regimens? \",\n    \"Which specific tumor types and prior-therapy backgrounds benefit most, and which derive little or no benefit from this sensitization approach? \",\n    \"Can biomarkers from the interferon and antigen-presentation signatures be used to select patients most likely to benefit before treatment? \"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_idqOWenzjnaTXcbXlBijaRna"
          }
        ],
        "usage": {
          "promptTokens": 10812,
          "cachedTokens": 7808,
          "responseTokens": 794,
          "thinkingTokens": 1089,
          "totalTokens": 12695
        },
        "costUsd": 0.0047122
      },
      {
        "step": 14,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"headline\": \"Tumor-targeted mRNA vaccines may prime cancers for stronger anti-PD-L1 responses\",\nL3:   \"plain_language_summary\": \"Researchers tested whether giving an mRNA vaccine directly inside a tumor can make that tumor more sensitive to immune checkpoint blockade. In mice, combining intratumoral mRNA vaccination with anti-PD-L1 was linked to stronger immune signatures, including broader antigen presentation, higher PD-L1 expression, and more CD8+ T-cell infiltration. In a separate retrospective review of 130 metastatic patients on ICI treatment, vaccinated patients (43) had better survival\nL4:   \",\nL5:   \"what_is_new\": [\nL6:     \"The work links local mRNA vaccination in the tumor with broadening of the tumor immunopeptidome and MHC-I presented antigens, which can improve immune recognition of the tumor. \",\nL7:     \"It combines murine efficacy experiments with a real-world metastatic patient analysis to connect mechanism, preclinical response, and retrospective clinical associations. \",\nL8:     \"Mechanistically, the effect appears tied to type I interferon signaling, with anti-IFNAR1 blockade abolishing sensitization and non-mRNA lipid particles failing to mimic the benefit.\"\nL9:   ],\nL10:   \"why_caution_is_needed\": [\nL11:     \"The human comparison was retrospective and non-randomized, so unmeasured confounding and baseline group differences could influence survival associations. \",\nL12:     \"Vaccination timing relative to ICI start varied across patients, making it hard to attribute timing-specific efficacy claims to the vaccine effect alone. \",\nL13:     \"Tumor-type mix and prior treatment heterogeneity were present, and mouse-to-human translation is not guaranteed across all cancers and contexts. \"\nL14:   ],\nL15:   \"glossary\": [\nL16:     {\nL17:       \"term\": \"ICI\",\nL18:       \"definition\": \"Immune checkpoint inhibitors; drugs like anti-PD-L1 that block inhibitory signals on immune cells so T-cells can attack tumors more effectively.\"\nL19:     },\nL20:     {\nL21:       \"term\": \"MHC-I\",\nL22:       \"definition\": \"A surface molecule type on cells that presents protein fragments to CD8+ T-cells, helping immune cells recognize cancer cells.\"\nL23:     },\nL24:     {\nL25:       \"term\": \"Interferon signaling\",\nL26:       \"definition\": \"A cell communication pathway (especially type I interferons) that increases antiviral-like immune activation and antigen presentation in tissues.\"\nL27:     },\nL28:     {\nL29:       \"term\": \"Immunopeptidome\",\nL30:       \"definition\": \"The full set of peptides displayed on MHC molecules by a cell, which can be measured to estimate how visible that cell is to the immune system.\"\nL31:     }\nL32:   ],\nL33:   \"open_questions\": [\nL34:     \"Do these findings hold in a prospective randomized human trial with predefined vaccination timing and standardized ICI regimens? \",\nL35:     \"Which specific tumor types and prior-therapy backgrounds benefit most, and which derive little or no benefit from this sensitization approach? \",\nL36:     \"Can biomarkers from the interferon and antigen-presentation signatures be used to select patients most likely to benefit before treatment? \"\nL37:   ]\nL38: }",
            "callId": "call_MCdyf6UI0WyXPogtCyAXEYUf"
          }
        ],
        "usage": {
          "promptTokens": 11623,
          "cachedTokens": 10624,
          "responseTokens": 32,
          "thinkingTokens": 54,
          "totalTokens": 11709
        },
        "costUsd": 0.0006873499999999999
      },
      {
        "step": 15,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "grep_search",
            "input": {
              "pattern": "clinical practice",
              "dir_path": "output",
              "include": null,
              "exclude_pattern": null,
              "names_only": false,
              "max_matches_per_file": 20,
              "total_max_matches": 20
            },
            "output": "output/public_summary.json:3:  \"plain_language_summary\": \"Researchers tested whether giving an mRNA vaccine directly inside a tumor can make that tumor more sensitive to immune checkpoint blockade. In mice, combining intratumoral mRNA vaccination with anti-PD-L1 was linked to stronger immune signatures, including broader antigen presentation, higher PD-L1 expression, and more CD8+ T-cell infiltration. In a separate retrospective review of 130 metastatic patients on ICI treatment, vaccinated patients (43) had better survival signals than unvaccinated patients (87), with a reported p-value of 0.01. The study also found that the benefit depended on type I interferon pathways and was lost when interferon signaling was blocked, and non-mRNA particle controls failed to reproduce the effect. While encouraging, the human signal is observational and not randomized, so larger prospective trials are still needed before changing clinical practice.",
            "callId": "call_pLBRMkmVaLYkIQguB4tmPuph"
          }
        ],
        "usage": {
          "promptTokens": 12397,
          "cachedTokens": 11520,
          "responseTokens": 54,
          "thinkingTokens": 1961,
          "totalTokens": 14412
        },
        "costUsd": 0.00453725
      },
      {
        "step": 16,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination can broaden tumor antigen presentation and increase immune visibility.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Broader antigen display after intratumoral mRNA vaccination\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        }\n      ],\n      \"caveat\": \"Mechanistic readouts were not uniformly strong across all tested model systems, so effect size may vary by context.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"The treatment strategy induces type I interferon-associated signaling and increases PD-L1 pathway activity, supporting combination with checkpoint blockade.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\n          \"line_ref\": \"L31\"\n        },\n        {\n          \"quote\": \"Interferon-associated antigen processing and presentation pathways increase.\",\n          \"line_ref\": \"L43\"\n        },\n        {\n          \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\n          \"line_ref\": \"L45\"\n        }\n      ],\n      \"caveat\": \"The report emphasizes that some mechanistic readouts were strongest in specific models rather than universal across all settings.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Combination of intratumoral mRNA vaccine and anti-PD-L1 produced stronger antitumor immune signatures than controls in the preclinical murine arm.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\",\n          \"line_ref\": \"L14\"\n        },\n        {\n          \"quote\": \"Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy\",\n          \"line_ref\": \"L33\"\n        }\n      ],\n      \"caveat\": \"Response-level details and statistical analyses for each model are not fully enumerated in the summary, limiting certainty about magnitude across tumors.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Vaccinated metastatic patients showed an associated survival advantage under ICI treatment compared with unvaccinated patients in the retrospective cohort.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n          \"line_ref\": \"L49\"\n        }\n      ],\n      \"caveat\": \"Because the cohort analysis is non-randomized with variable vaccination timing and treatment heterogeneity, causality cannot be inferred.\"\n    }\n  ]\n}"
            },
            "output": "Successfully wrote file: output/claim_audit.json",
            "callId": "call_a9cyZyHP0I0TaZG1Fp16tWK6"
          }
        ],
        "usage": {
          "promptTokens": 12644,
          "cachedTokens": 12288,
          "responseTokens": 849,
          "thinkingTokens": 1720,
          "totalTokens": 15213
        },
        "costUsd": 0.0055341999999999995
      },
      {
        "step": 17,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": 0,
              "limit": null
            },
            "output": "L1: {\nL2:   \"claims\": [\nL3:     {\nL4:       \"claim_id\": \"C01\",\nL5:       \"claim\": \"Intratumoral mRNA vaccination can broaden tumor antigen presentation and increase immune visibility.\",\nL6:       \"strength\": \"strong\",\nL7:       \"evidence\": [\nL8:         {\nL9:           \"quote\": \"Broader antigen display after intratumoral mRNA vaccination\",\nL10:           \"line_ref\": \"L28\"\nL11:         },\nL12:         {\nL13:           \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\nL14:           \"line_ref\": \"L44\"\nL15:         }\nL16:       ],\nL17:       \"caveat\": \"Mechanistic readouts were not uniformly strong across all tested model systems, so effect size may vary by context.\"\nL18:     },\nL19:     {\nL20:       \"claim_id\": \"C02\",\nL21:       \"claim\": \"The treatment strategy induces type I interferon-associated signaling and increases PD-L1 pathway activity, supporting combination with checkpoint blockade.\",\nL22:       \"strength\": \"strong\",\nL23:       \"evidence\": [\nL24:         {\nL25:           \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\nL26:           \"line_ref\": \"L31\"\nL27:         },\nL28:         {\nL29:           \"quote\": \"Interferon-associated antigen processing and presentation pathways increase.\",\nL30:           \"line_ref\": \"L43\"\nL31:         },\nL32:         {\nL33:           \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\nL34:           \"line_ref\": \"L45\"\nL35:         }\nL36:       ],\nL37:       \"caveat\": \"The report emphasizes that some mechanistic readouts were strongest in specific models rather than universal across all settings.\"\nL38:     },\nL39:     {\nL40:       \"claim_id\": \"C03\",\nL41:       \"claim\": \"Combination of intratumoral mRNA vaccine and anti-PD-L1 produced stronger antitumor immune signatures than controls in the preclinical murine arm.\",\nL42:       \"strength\": \"moderate\",\nL43:       \"evidence\": [\nL44:         {\nL45:           \"quote\": \"Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\",\nL46:           \"line_ref\": \"L14\"\nL47:         },\nL48:         {\nL49:           \"quote\": \"Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy\",\nL50:           \"line_ref\": \"L33\"\nL51:         }\nL52:       ],\nL53:       \"caveat\": \"Response-level details and statistical analyses for each model are not fully enumerated in the summary, limiting certainty about magnitude across tumors.\"\nL54:     },\nL55:     {\nL56:       \"claim_id\": \"C04\",\nL57:       \"claim\": \"Vaccinated metastatic patients showed an associated survival advantage under ICI treatment compared with unvaccinated patients in the retrospective cohort.\",\nL58:       \"strength\": \"tentative\",\nL59:       \"evidence\": [\nL60:         {\nL61:           \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\nL62:           \"line_ref\": \"L30\"\nL63:         },\nL64:         {\nL65:           \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL66:           \"line_ref\": \"L49\"\nL67:         }\nL68:       ],\nL69:       \"caveat\": \"Because the cohort analysis is non-randomized with variable vaccination timing and treatment heterogeneity, causality cannot be inferred.\"\nL70:     }\nL71:   ]\nL72: }",
            "callId": "call_p8mUbYln3qmM3Y9VRv9Q3Arr"
          }
        ],
        "usage": {
          "promptTokens": 13512,
          "cachedTokens": 12544,
          "responseTokens": 34,
          "thinkingTokens": 157,
          "totalTokens": 13703
        },
        "costUsd": 0.0009376
      },
      {
        "step": 18,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"Intratumoral mRNA vaccination may make tumors more responsive to anti-PD-L1 therapy\",\n  \"plain_language_summary\": \"Researchers tested whether delivering an mRNA vaccine directly into a tumor could sensitize cancers to immune checkpoint blockade. In multiple mouse models, adding intratumoral mRNA vaccination to anti-PD-L1 therapy was associated with broader tumor antigen presentation, higher type I interferon signaling, increased PD-L1 levels, and greater intratumoral CD8+ T-cell density. In a retrospective review of 130 metastatic patients treated with ICI, 43 vaccinated patients had better survival than 87 unvaccinated patients, with a reported p-value of 0.01. The study also showed that the benefit depended on interferon signaling and was lost when IFNAR1 signaling was blocked, and that non-mRNA particle controls did not reproduce the effect. The authors note this was preclinical plus retrospective evidence, so prospective randomized trials are still needed before clinical decisions can change.\",\n  \"what_is_new\": [\n    \"A local mRNA vaccine strategy appears to broaden both the immunopeptidome and MHC-I peptide presentation in tumors, potentially improving immune recognition.\",\n    \"The work connects mechanistic murine evidence with a human retrospective association, suggesting a biologic rationale and a clinical signal from the same intervention concept.\",\n    \"The report identifies type I interferon signaling as an essential mediator, with anti-IFNAR1 blockade removing the sensitization benefit and mRNA-free lipid particles failing to mimic it.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human comparison was retrospective and non-randomized, so unmeasured confounding and baseline differences could influence survival associations.\",\n    \"Vaccination timing relative to ICI start varied among patients, which weakens causal interpretation of the survival signal.\",\n    \"Tumor types and prior treatment histories were mixed, and mouse model findings may not translate uniformly across all human cancers.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"ICI\",\n      \"definition\": \"Immune checkpoint inhibitors such as anti-PD-L1 that remove inhibitory signaling and can reactivate T-cell anti-tumor activity.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A checkpoint ligand on tumor cells that can suppress T-cell function; anti-PD-L1 therapy blocks this inhibitory signal.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A major histocompatibility complex class I molecule that presents peptides to CD8+ T-cells for immune recognition.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The set of peptides presented by MHC molecules on a cell, used as a readout of antigen visibility to the immune system.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Can these findings be confirmed in a prospective randomized trial with fixed vaccine timing and standardized ICI regimens?\",\n    \"Which tumor histologies and prior treatment backgrounds benefit most from this sensitization strategy, and which derive little benefit?\",\n    \"Can interferon and antigen-presentation signatures be used as practical biomarkers to select patients likely to respond?\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_mzjnWCUSecoXD4JcyepTIVs1"
          }
        ],
        "usage": {
          "promptTokens": 14480,
          "cachedTokens": 13312,
          "responseTokens": 758,
          "thinkingTokens": 2686,
          "totalTokens": 17924
        },
        "costUsd": 0.0075128
      },
      {
        "step": 19,
        "modelVersion": "chatgpt-gpt-5.3-codex-spark",
        "text": "âœ… **Completed output files**\n\n- [x] `output/study_overview.json`\n- [x] `output/quantitative_findings.json`\n- [x] `output/claim_audit.json`\n- [x] `output/public_summary.json`",
        "toolCalls": [],
        "usage": {
          "promptTokens": 15255,
          "cachedTokens": 14336,
          "responseTokens": 59,
          "thinkingTokens": 1333,
          "totalTokens": 16647
        },
        "costUsd": 0.00337215
      }
    ],
    "totalCostUsd": 0.04394135
  }
}
